| Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine : a multicenter prospective observational study in Switzerland | The Lancet regional health. Europe |  | | 2024 | 11 | 108 |
|
| Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV | Frontiers in pharmacology | | | 2024 | 10 | 94 |
|
| Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV | Clinical pharmacology and therapeutics | | | 2024 | 95 | 330 |
|
| Study protocol for assessment of the efficacy of calcium dobesilate versus placebo on SARS-CoV-2 viral load in outpatients with COVID-19 (CADOVID study): a randomised, placebo-controlled, double-blind, monocentric phase II trial | BMJ open | | | 2024 | 34 | 120 |
|
| Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study | BMC pharmacology & toxicology | | | 2023 | 67 | 165 |
|
| SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients | Vaccines | | | 2023 | 96 | 152 |
|
| Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial | Trials | | | 2022 | 143 | 263 |
|
| Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals | Frontiers in immunology | | | 2022 | 261 | 152 |
|
| Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland | Pharmaceutics | | | 2022 | 75 | 202 |
|
| Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial | EClinicalMedicine | | | 2021 | 653 | 221 |
|
